2021
DOI: 10.1016/j.jacc.2020.12.047
|View full text |Cite
|
Sign up to set email alerts
|

3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
69
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 122 publications
(73 citation statements)
references
References 23 publications
4
69
0
Order By: Relevance
“…In contrast, the MITRA-FR study included more patients with severe left ventricular dysfunction and a relatively less severe MR as a major cause of HF. Results of the extended 3-year follow-up of patients in the COAPT study confirmed the effectiveness of TMVR with the Mitr-aClip system in reducing mortality and rehospitalization rates and improving the quality of life [8].…”
Section: Randomized Trialsmentioning
confidence: 66%
“…In contrast, the MITRA-FR study included more patients with severe left ventricular dysfunction and a relatively less severe MR as a major cause of HF. Results of the extended 3-year follow-up of patients in the COAPT study confirmed the effectiveness of TMVR with the Mitr-aClip system in reducing mortality and rehospitalization rates and improving the quality of life [8].…”
Section: Randomized Trialsmentioning
confidence: 66%
“…A recent work of COAPT with extended follow-up through 36 months demonstrated that there was no loss of effectiveness with Mitra-Clip treatment nor did new safety concerns emerge. 131 In addition, compared with patients who continued treatment with GDMT alone, patients assigned to GDMT alone who crossed over and received a MitraClip experienced fewer subsequent heart failure hospitalizations and deaths, with rates comparable with patients originally treated with the MitraClip. Thus, patients meeting COAPT eligibility criteria might benefit from MitraClip reduction of severe mitral regurgitation even after an extended period of GDMT.…”
Section: Chapter 4 Nonpharmacologic Therapy Percutaneous Mitral Valve Repair System (Mitraclip)mentioning
confidence: 99%
“…A recent work of COAPT with extended follow-up through 36 months demonstrated that there was no loss of effectiveness with MitraClip ® treatment nor did new safety concerns emerge. 131 In addition, compared with patients who continued treatment with GDMT alone, patients assigned to GDMT alone who crossed over and received a MitraClip ® experienced fewer subsequent heart failure hospitalizations and deaths, with rates comparable with patients originally treated with the MitraClip ® . Thus, patients meeting COAPT eligibility criteria might benefit from MitraClip ® reduction of severe mitral regurgitation even after an extended period of GDMT.…”
Section: Nonpharmacologic Therapy 1 Percutaneous Mitral Valve Repair System (Mitraclip ® )mentioning
confidence: 99%